FDA Approves OSELTAMIVIR PHOSPHATE — Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited announced the FDA approval of its ANDA for oseltamivir phosphate oral powder, positioning the company in the market for this essential influenza treatment. The approval expands Alembic’s portfolio ahead of the 2026-27 respiratory season, offering a potential entry point as a new generic alternative.